Autolus Therapeutics ↗
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Autolus Therapeutics
Revenue$1.7MFY 2023
Operating income−$180M▼ 25.3% YoY
Net profit−$208M▼ 40.0% YoY
Shareholders' equity$111M
Market cap$377MAUTL · $1.42
About Autolus Therapeutics
Company details
- Website
- autolus.com
- Founded
- 2018
- Listed
- Nasdaq: AUTL (since 2018)
Company summary
Legal nameAutolus Therapeutics plc
TickerAUTL
ExchangeNasdaq
CountryUnited Kingdom
SEC CIK0001730463
Listed since2018
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorOther Industries · Discovered Companies
Websitehttp://www.autolus.com
US market & SEC filings
AUTL · Nasdaq · SEC CIK 0001730463
Last price · 04 Nov 2026
$1.42
−0.35%
Market cap$377M
P/E—On FY 2023 diluted EPS
Volume2,883,285
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited KingdomListed 2018
AUTL share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Websitehttp://www.autolus.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.